Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹ ...

GAMMAGARD LIQUID ERC is a ready-to-use liquid immunoglobulin therapy with an IgA content of less than or equal to 2 µg/mL in a 10% solution to be administered intravenously or subcutaneously.

In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin eye drop for the treatment of dry eye disease, according to a press ...

Vanrafia is an endothelin receptor antagonist. Here's how it treats immunoglobulin A nephropathy.

The European Task Force unveils critical updates on Guillain-Barré syndrome, highlighting new treatment strategies and diagnostic criteria for clinicians.

A study has established the importance of immunoglobulin A, an antibody that is part of the immune system, in generating a response to pneumonia vaccines. Researchers have found that the absence ...

Topline data were announced from a phase 2/3 trial evaluating Flebogamma 5% DIF (immune globulin intravenous ) in patients with post-polio syndrome (PPS).

Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial.

Create stunning diagrams in seconds with Excalidraw’s AI-powered features. Customize, collaborate, and export with ease.